Segall Bryant & Hamill LLC Decreases Stake in BioCryst Pharmaceuticals, Inc. $BCRX

Segall Bryant & Hamill LLC cut its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 8.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,220,077 shares of the biotechnology company’s stock after selling 110,237 shares during the period. Segall Bryant & Hamill LLC owned about 0.58% of BioCryst Pharmaceuticals worth $10,932,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of BCRX. Cerity Partners LLC boosted its holdings in BioCryst Pharmaceuticals by 203.6% in the first quarter. Cerity Partners LLC now owns 36,410 shares of the biotechnology company’s stock valued at $273,000 after purchasing an additional 24,418 shares during the last quarter. Allianz Asset Management GmbH raised its position in shares of BioCryst Pharmaceuticals by 9.6% in the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company’s stock valued at $103,000 after purchasing an additional 1,200 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of BioCryst Pharmaceuticals during the 1st quarter valued at approximately $125,000. Mackenzie Financial Corp grew its position in shares of BioCryst Pharmaceuticals by 37.3% during the first quarter. Mackenzie Financial Corp now owns 116,258 shares of the biotechnology company’s stock worth $872,000 after buying an additional 31,596 shares in the last quarter. Finally, Federated Hermes Inc. increased its stake in shares of BioCryst Pharmaceuticals by 10.1% in the first quarter. Federated Hermes Inc. now owns 184,904 shares of the biotechnology company’s stock worth $1,387,000 after buying an additional 16,947 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BCRX has been the topic of a number of research analyst reports. Barclays reduced their price objective on shares of BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 4th. Cantor Fitzgerald increased their price target on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 15th. Evercore ISI reissued an “in-line” rating and issued a $8.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Needham & Company LLC cut their price objective on BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. Finally, Zacks Research downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Ten equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

BioCryst Pharmaceuticals Stock Down 0.9%

Shares of NASDAQ:BCRX opened at $6.97 on Monday. The company has a market cap of $1.47 billion, a PE ratio of -38.72 and a beta of 1.09. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.31. The firm has a 50-day simple moving average of $7.22 and a 200 day simple moving average of $8.53.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The business had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. The firm’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.07) EPS. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.